A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (Sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)
Latest Information Update: 30 Jan 2023
At a glance
- Drugs Sirukumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SIRROUND-LTE
- Sponsors Janssen Research & Development; Janssen-Cilag
- 31 Aug 2018 Status changed from active, no longer recruiting to completed.
- 12 Jun 2018 Trial has been completed in Poland (End date: 2018-05-01).
- 07 Jun 2018 Trial has been completed in Austria (End date: 2018-05-01).